Sep 10, 2020 / 12:00PM GMT
Andrew Simon Baum - Citigroup Inc., Research Division - Global Head of Healthcare Research and MD
Good morning, or good afternoon to those of you in Europe.
This is Andrew Baum from Citi's global health care team, delighted to introduce our next session.
As you'll see from the roster of familiar faces above me, we have the management from Merck, namely Roy Baynes, the Chief Development Officer and Chief Medical Officer; and Peter Dannenbaum, the Head of Investor Relations. Many thanks, both of you, for joining us.
We've got about 45 minutes. I want to keep it a free-flowing discussion. (Operator Instructions)
Questions and Answers:
Andrew Simon Baum - Citigroup Inc., Research Division - Global Head of Healthcare Research and MDSo maybe a leading question, to start. A criticism that we get from investors, and obviously we've been a very long-term bull of immuno-oncology and Merck in particular, is that there is too much dependency on KEYTRUDA. The durability of KEYTRUDA is questioned in terms of biosimilar entrants. And more
Trustpilot
